

Special Issue

The Pathophysiology of Preeclampsia

Message from the Guest Editor

Preeclampsia is a multisystem, specific for human pregnancy, disease, and is a cause of serious complications for both the pregnant woman and her baby. Preeclampsia may lead to foetal growth restriction (FGR), premature birth, or intrauterine foetal death. In severe cases, an attack of eclamptic seizures, premature separation of the placenta, DIC, intracranial haemorrhage, HELLP syndrome, renal failure, and even maternal and foetal death may occur. The aim of this Special Issue is to provide a review of aetiopathogenesis of preeclampsia. Laboratory and clinical researchers are welcomed to submit their works that contribute to better pregnancy outcomes in preeclamptic women. Thus, all original research articles or reviews on topics related to pregnancy in women with preeclampsia and HELLP syndrome are welcome in this Special Issue. Topics will include:

- Preeclampsia and hypertension in pregnant women— aetiopathogenesis, pathophysiology, causes, complications;
- HELLP syndrome—diagnosis, pathophysiology;
- Placenta in preeclampsia—what has gone wrong;
- Foetal complications.

Guest Editor

Prof. Dr. Marzena Laskowska

Department of Obstetrics and Perinatology, Medical University of Lublin, Lublin, Poland

Deadline for manuscript submissions

closed (31 January 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/122669

Biomedicines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2024).